Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Astellas Halts Development of Stroke Prevention Drug Darexaban

Sept. 28 (Bloomberg) -- Astellas Pharma Inc. will discontinue global development of darexaban maleate, a drug for preventing strokes and blood clots, because competition has increased in the sector and it can’t find a partner to develop and commercialize the drug.

The discontinuation won’t affect the Japanese drugmaker’s earnings forecast for this fiscal year, according to a statement on Astellas’ website today.

Link to Company News:{4503 JP <Equity> CN <GO>}

To contact the reporter on this story: Go Onomitsu in Tokyo at

To contact the editor responsible for this story: Gearoid Reidy at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.